- Home
- SEED vs QNRX Comparison
SEED vs QNRX Comparison
Compare SEED & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | QNRX |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SEED | QNRX |
|---|---|---|
| Price | $1.32 | $10.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.0K | ★ 37.7K |
| Earning Date | 02-09-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,910,081.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $5.01 |
| 52 Week High | $2.70 | $41.80 |
Technical Indicators
Market Signals| Indicator | SEED | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 36.15 |
| Support Level | $1.12 | $10.88 |
| Resistance Level | $1.20 | $11.88 |
| Average True Range (ATR) | 0.07 | 0.91 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 85.19 | 0.00 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.